ASH Annual Meeting and Exposition | Conference

Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCL

December 10th 2017

Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.

Direct Oral Anticoagulant Prevents VTE Recurrence in Select Patients With Cancer

December 9th 2017

Treatment using oral rivaroxaban (Xarelto) reduced venous thromboembolism (VTE) recurrence among patients with cancer, according to results from the select-d trial.

Oncology Experts Highlight Practice-Changing Abstracts at ASH 2017

December 8th 2017

Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.

Dr. Chaudhary on Remaining Challenges With CAR T-Cell Therapy

January 25th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses challenges that oncologists continue to face when treating patients with CAR T-cell therapy.

Expert Discusses Key Daratumumab Data Presented at ASH

January 25th 2017

Saad Z. Usmani, MD, discusses the latest developments with daratumumab in the treatment of patients with multiple myeloma, many of which were presented at the recent 2016 ASH Annual Meeting.

Expert Touts Value of Lenalidomide Maintenance in Myeloma

January 19th 2017

Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.

Dr. Goy on the Role of MRD in Mantle Cell Lymphoma

January 18th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of minimal residual disease in the treatment of patients with mantle cell lymphoma.

Dr. Kelly on Racial Disparities in Multiple Myeloma

January 13th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Dr. Goy on Combination Therapies in Mantle Cell Lymphoma

January 12th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combination therapies currently being explored in the treatment of patients with mantle cell lymphoma.

Transplant Remains Pivotal in Myeloma, Other Hematologic Cancers

January 2nd 2017

The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.

Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia

December 31st 2016

Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.

Expert Explains WHO Classification Refinements in Hematologic Malignancies

December 30th 2016

Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.

Dr. Mascarenhas on the MPD-RC 112 Study in PV and ET

December 30th 2016

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.

Myeloma Expert Highlights Practice-Changing ASH Findings

December 29th 2016

The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further.

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

December 29th 2016

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

Dr. Daver on Immune Checkpoint Pathways in AML

December 28th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.

Lenalidomide Shows Activity in Low-Risk MDS

December 22nd 2016

Results from the randomized phase II HOVON89 trial showed that nearly 40% of patients with low intermediate-1 risk myelodysplastic syndrome who were refractory to erythropoietin and granulocyte-colony stimulating factor experienced hematologic improvement with erythroid response after being treated with lenalidomide monotherapy.

Dr. Perales on the PROGRESS II Trial in Hematologic Malignancies

December 22nd 2016

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, provides an overview of the PROGRESS II trial, which was conducted for patients with hematologic malignancies.

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL

December 22nd 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.

Venetoclax Active in Heavily Treated Multiple Myeloma

December 21st 2016

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.